Cholestagel indgivet sammen med en 3- hydroxy- 3- methyl- glutaryl- coenzym A (HMG- CoA) reduktasehæmmer (statin) er indiceret som supplerende behandling til diæt med henblik på at fremkalde en yderligere reduktion i niveauet af low density lipoprotein- kolesterol (LDL- C) hos voksne patienter med primær hyperkolesterolæmi, der ikke kontrolleres tilstrækkeligt med statin alene.
Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density lipoprotein cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.